New eye injection targets two causes of vision loss in wet AMD

NCT ID NCT05456828

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called ASKG712 in 56 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and works by blocking two proteins that fuel abnormal blood vessel growth. The main goals were to check safety and how the drug moves through the body, with some early looks at vision outcomes. The trial has been completed, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ASKG712 (a protein that blocks two growth factors involved in abnormal blood vessel growth in the eye)
What this could lead to
If successful, this could lead to a new treatment option for wet age-related macular degeneration that targets two pathways at once, potentially offering better or longer-lasting vision protection.
What could go wrong
This is an early Phase 1/2a study with only 56 participants, so safety and effectiveness are not yet proven. The treatment is injected directly into the eye, which carries risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.